Back to results

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Primary Purpose

B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer

Status

Completed

Phase

Phase 1

Locations

International

Study Type

Interventional

Intervention

Nivolumab

Epacadostat

Chemotherapy

About this trial

This is an interventional treatment trial for B-cell Malignancies

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Male or female subjects, age 18 years or older
Subjects with histologically or cytologically confirmed NSCLC, MEL (including I/O relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL or HL, or glioblastoma
Presence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of measurable disease is not required.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of the most recent prior chemotherapy regimen) are required for all cohorts except glioblastoma

Exclusion Criteria:

Laboratory and medical history parameters not within Protocol-defined range
Currently pregnant or breastfeeding
Subjects who have received prior immune checkpoint inhibitors or an IDO inhibitor (except select Phase 2 cohorts evaluating I/O relapsed or I/O refractory MEL). Subjects who have received experimental vaccines or other immune therapies should be discussed with the medical monitor to confirm eligibility
Untreated central nervous system (CNS) metastases or CNS metastases that have progressed
Subjects with any active or inactive autoimmune process
Evidence of interstitial lung disease or active, noninfectious pneumonitis
Subjects with any active or inactive autoimmune process
Ocular MEL

Sites / Locations

UAB Comprehensive Cancer Center
The Angeles Clinic and Research Institute
USC Norris Cancer Center
UCSF - University of California San Francisco
University of Colorado Anschutz Medical Campus
The University of Kansas Clinical Research Center
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Dana Farber Cancer Institute
Lahey Hospital & Medical Center
NYU Cancer Center
Columbia University, Herbert Irving Comprehensive Cancer Center
Duke University Medical Center
Wake Forest Medical Center Boulevard
Sanford Research
University of Pittsburgh School of Medicine
Sanford Research
Vanderbilt University Medical Center
Texas Oncology Research
MD Anderson Cancer Center
Utah Cancer Specialists
Huntsman Cancer Institute
Medical College of Wisconsin
The Christie NHS Foundation Trust
Oxford University Hospitals NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Arm Label

Phase 1 Part 1 Epacadostat 25mg BID +Nivolumab

Phase 1 Part 1 Epacadostat 50mg BID +Nivolumab

Phase 1 Part 1 Epacadostat 100mg BID +Nivolumab

Phase 1 Part 1 Epacadostat 300mg BID +Nivolumab

Phase 1 Part 2 Epacadostat 100mg BID +Nivolumab +5-FU/Platinum

Phase 1 Part 2 Epacadostat 100mg BID +Pemetrexed/Platinum

Phase 1 Part 2 Epacadostat 100mg BID +Paclitaxel/Platinum

Phase 2 Epacadostat 100mg BID + Nivolumab

Phase 2 Epacadostat 300mg BID + Nivolumab

Arm Description

Epacadostat 25mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W

Epacadostat 50mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.

Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360mg Q3W and 5-FU/Platinum( Carboplatin or Cisplatin+5-Fluorouracil) administered intravenously (IV).

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Pemetrexed/Platinum (Carboplatin orCisplatin+Pemetrexed) administered intravenously (IV).

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Paclitaxel/Platinum(Carboplatin+Cisplatin+Paclitaxel)administered intravenously (IV).

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W or 480 mg Q4W based on tumor type administered intravenously (IV).

Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W administered intravenously (IV).

Outcomes

Primary Outcome Measures

Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as occurrence of any treatment-emergent adverse event (TEAE) in Phase 1 Parts 1 and 2. DLT included all TEAE of specified grades such as 1) Hematologic toxicities - any Grade 4 thrombocytopenia or neutropenia, anemia, febrile neutropenia, ≥ Grade 3 hemolysis, thrombocytopenia and 2) Nonhematologic toxicities - Grade 4 AE, nausea, vomiting, or diarrhea, electrolyte abnormality, ≥ Grade 3 aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin elevation, Grade 2 AST/ALT with symptomatic liver inflammation, AST or ALT > 3 × upper limit of normal (ULN) and concurrent total bilirubin > 2 × ULN without initial findings of cholestasis, and any other ≥ Grade 3 toxicity. A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and up to 100 days after last dose of study drug.

Phase 1, Part 2: Number of Participants With Dose Limiting Toxicities (DLTs)

Phase 1, Parts 1 and 2: Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and up to 100 days after last dose of study drug.

Phase 2: Objective Response Rate (ORR) in Participants With Select Solid Tumors Per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 for Participants With Solid Tumors and Per Cheson Criteria for Participants With DLBCL

ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per RECIST v1.1. CR per RECIST v 1.1 was defined as disappearance of all target lesions. PR per RECIST v 1.1 was defined as At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. Data is reported as per dose received by the participants with a particular cancer type. CR per Cheson criteria was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR per Cheson criteria was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses.

Phase 2: Progression Free Survival (PFS)

PFS is defined as the time from randomization to the first documented progressive disease per RECIST v1.1 or death due to any cause, whichever occurs first.

Phase 2: Overall Survival (OS) Rate of Proportion With Glioblastoma

OS rate is defined as the proportion of participants alive 9 months after the start of treatment.

Secondary Outcome Measures

Phase 1, Part 2: ORR Per RECIST v1.1 and for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC

Phase 1, Part 1: ORR Per RECIST v1.1 for Participants With Solid Tumors; Per Cheson Criteria for Participants With B-cell NHL; and Per RANO and mRANO Criteria for Participants With GBM

ORR was defined as percentage of participants having CR or PR as determined by investigator assessment of radiographic disease per RECIST v1.1. CR per RECIST v 1.1 was defined as disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. Per Cheson criteria, CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR: at least a 50% decrease in SPD of up to 6 of the largest dominant nodes or nodal masses. Per RANO criteria, CR: Complete disappearance of all enhancing measurable and non-measurable disease sustained. PR: at least ≥50% decrease compared with baseline in the SOD of all measurable enhancing lesions sustained.

Phase 1, Part 2: Duration of Response (DOR) for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC

DOR is defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of the participant's death and first overall response of PD. CR was defined as disappearance of all target lesions. PR was defined as At least a 30% decrease in the SOD of target lesions, taking as reference the Baseline sum diameters. PD was defined as at least a 20% increase in the SOD of target lesions.

Phase 1, Part 2: PFS for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC

PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first.

Phase 2: Duration of Response

DOR is defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of the participant's death and first overall response of PD. CR was defined as disappearance of all target lesions. PR was defined as At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. PD was defined as at least a 20% increase in the SOD of target lesions.

Phase 2: Duration of Disease Control, Defined as CR, PR, and Stable Disease (SD)

Duration of disease control is the time from the first dose to the first objective response of PD, or death, whichever occurs first, for participants who reported a best overall response of SD or better. PD was defined as at least a 20% increase in the SOD of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the Baseline sum diameters.

Phase 2: Safety and Tolerability Measured by the Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Fatal Treatment Emergent AEs

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and up to 100 days after last dose of study drug. Adverse events of grade 5 which result in death are called as fatal AEs.

Full Information

NCT ID

NCT02327078

First Posted

December 1, 2014

Last Updated

April 24, 2023

Sponsor

Incyte Corporation

Collaborators

Bristol-Myers Squibb

1. Study Identification

Unique Protocol Identification Number

NCT02327078

Brief Title

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Official Title

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Study Type

Interventional

2. Study Status

Record Verification Date

April 2023

Overall Recruitment Status

Completed

Study Start Date

November 26, 2014 (Actual)

Primary Completion Date

June 16, 2020 (Actual)

Study Completion Date

June 16, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Incyte Corporation

Collaborators

Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1, Phase 2

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

307 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Phase 1 Part 1 Epacadostat 25mg BID +Nivolumab

Arm Type

Experimental

Arm Description

Epacadostat 25mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W

Arm Title

Phase 1 Part 1 Epacadostat 50mg BID +Nivolumab

Arm Type

Experimental

Arm Description

Epacadostat 50mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W

Arm Title

Phase 1 Part 1 Epacadostat 100mg BID +Nivolumab

Arm Type

Experimental

Arm Description

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.

Arm Title

Phase 1 Part 1 Epacadostat 300mg BID +Nivolumab

Arm Type

Experimental

Arm Description

Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab administered intravenously (IV) at 3mg/kg Q2W.

Arm Title

Phase 1 Part 2 Epacadostat 100mg BID +Nivolumab +5-FU/Platinum

Arm Type

Experimental

Arm Description

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360mg Q3W and 5-FU/Platinum( Carboplatin or Cisplatin+5-Fluorouracil) administered intravenously (IV).

Arm Title

Phase 1 Part 2 Epacadostat 100mg BID +Pemetrexed/Platinum

Arm Type

Experimental

Arm Description

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Pemetrexed/Platinum (Carboplatin orCisplatin+Pemetrexed) administered intravenously (IV).

Arm Title

Phase 1 Part 2 Epacadostat 100mg BID +Paclitaxel/Platinum

Arm Type

Experimental

Arm Description

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 360 mg Q3W and Paclitaxel/Platinum(Carboplatin+Cisplatin+Paclitaxel)administered intravenously (IV).

Arm Title

Phase 2 Epacadostat 100mg BID + Nivolumab

Arm Type

Experimental

Arm Description

Epacadostat 100mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W or 480 mg Q4W based on tumor type administered intravenously (IV).

Arm Title

Phase 2 Epacadostat 300mg BID + Nivolumab

Arm Type

Experimental

Arm Description

Epacadostat 300mg oral twice daily (BID) continuous daily dosing in combination with Nivolumab 240mg Q2W administered intravenously (IV).

Intervention Type

Drug

Intervention Name(s)

Nivolumab

Intervention Description

specified dose and dosing schedule

Intervention Type

Drug

Intervention Name(s)

Epacadostat

Intervention Description

oral twice daily continuous at the protocol-defined dose

Intervention Type

Drug

Intervention Name(s)

Chemotherapy

Intervention Description

Specified dose on specified days

Primary Outcome Measure Information:

Title

Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

Description

Time Frame

Day 42

Title

Phase 1, Part 2: Number of Participants With Dose Limiting Toxicities (DLTs)

Description

Time Frame

Day 42

Title

Phase 1, Parts 1 and 2: Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

Description

Time Frame

up to approximately 39 months

Title

Description

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 2: Progression Free Survival (PFS)

Description

PFS is defined as the time from randomization to the first documented progressive disease per RECIST v1.1 or death due to any cause, whichever occurs first.

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 2: Overall Survival (OS) Rate of Proportion With Glioblastoma

Description

OS rate is defined as the proportion of participants alive 9 months after the start of treatment.

Time Frame

Month 9

Secondary Outcome Measure Information:

Title

Phase 1, Part 2: ORR Per RECIST v1.1 and for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC

Description

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 1, Part 1: ORR Per RECIST v1.1 for Participants With Solid Tumors; Per Cheson Criteria for Participants With B-cell NHL; and Per RANO and mRANO Criteria for Participants With GBM

Description

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 1, Part 2: Duration of Response (DOR) for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC

Description

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 1, Part 2: PFS for Participants With Advanced or Metastatic SCCHN and Advanced or Metastatic NSCLC

Description

PFS is defined as the time from randomization to the first documented progressive disease or death due to any cause, whichever occurs first.

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 2: Duration of Response

Description

DOR is defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of the participant's death and first overall response of PD. CR was defined as disappearance of all target lesions. PR was defined as At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. PD was defined as at least a 20% increase in the SOD of target lesions.

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 2: Duration of Disease Control, Defined as CR, PR, and Stable Disease (SD)

Description

Time Frame

From first dose up end of the study (up to approximately 6 years)

Title

Phase 2: Safety and Tolerability Measured by the Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Fatal Treatment Emergent AEs

Description

Time Frame

up to approximately 35 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Male or female subjects, age 18 years or older Subjects with histologically or cytologically confirmed NSCLC, MEL (including I/O relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL or HL, or glioblastoma Presence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of measurable disease is not required. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 Fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of the most recent prior chemotherapy regimen) are required for all cohorts except glioblastoma Exclusion Criteria: Laboratory and medical history parameters not within Protocol-defined range Currently pregnant or breastfeeding Subjects who have received prior immune checkpoint inhibitors or an IDO inhibitor (except select Phase 2 cohorts evaluating I/O relapsed or I/O refractory MEL). Subjects who have received experimental vaccines or other immune therapies should be discussed with the medical monitor to confirm eligibility Untreated central nervous system (CNS) metastases or CNS metastases that have progressed Subjects with any active or inactive autoimmune process Evidence of interstitial lung disease or active, noninfectious pneumonitis Subjects with any active or inactive autoimmune process Ocular MEL

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Lance Leopold

Organizational Affiliation

Incyte Corporation

Official's Role

Study Director

Facility Information:

Facility Name

UAB Comprehensive Cancer Center

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294

Country

United States

Facility Name

The Angeles Clinic and Research Institute

City

Los Angeles

State/Province

California

ZIP/Postal Code

90025

Country

United States

Facility Name

USC Norris Cancer Center

City

Los Angeles

State/Province

California

ZIP/Postal Code

90033

Country

United States

Facility Name

UCSF - University of California San Francisco

City

San Francisco

State/Province

California

ZIP/Postal Code

94115

Country

United States

Facility Name

University of Colorado Anschutz Medical Campus

City

Aurora

State/Province

Colorado

ZIP/Postal Code

80045

Country

United States

Facility Name

The University of Kansas Clinical Research Center

City

Fairway

State/Province

Kansas

ZIP/Postal Code

66205

Country

United States

Facility Name

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21231

Country

United States

Facility Name

Dana Farber Cancer Institute

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02215

Country

United States

Facility Name

Lahey Hospital & Medical Center

City

Burlington

State/Province

Massachusetts

ZIP/Postal Code

01805

Country

United States

Facility Name

NYU Cancer Center

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Facility Name

Columbia University, Herbert Irving Comprehensive Cancer Center

City

New York

State/Province

New York

ZIP/Postal Code

10032

Country

United States

Facility Name

Duke University Medical Center

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27710

Country

United States

Facility Name

Wake Forest Medical Center Boulevard

City

Winston-Salem

State/Province

North Carolina

ZIP/Postal Code

27157

Country

United States

Facility Name

Sanford Research

City

Fargo

State/Province

North Dakota

ZIP/Postal Code

58122

Country

United States

Facility Name

University of Pittsburgh School of Medicine

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15232

Country

United States

Facility Name

Sanford Research

City

North Sioux City

State/Province

South Dakota

ZIP/Postal Code

57104

Country

United States

Facility Name

Vanderbilt University Medical Center

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37232

Country

United States

Facility Name

Texas Oncology Research

City

Austin

State/Province

Texas

ZIP/Postal Code

78705

Country

United States

Facility Name

MD Anderson Cancer Center

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

Utah Cancer Specialists

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84106

Country

United States

Facility Name

Huntsman Cancer Institute

City

Salt Lake City

State/Province

Utah

ZIP/Postal Code

84112

Country

United States

Facility Name

Medical College of Wisconsin

City

Milwaukee

State/Province

Wisconsin

ZIP/Postal Code

53226

Country

United States

Facility Name

The Christie NHS Foundation Trust

City

Manchester

ZIP/Postal Code

M20 4BX

Country

United Kingdom

Facility Name

Oxford University Hospitals NHS Trust

City

Oxford

ZIP/Postal Code

OX3 7LJ

Country

United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

We'll reach out to this number within 24 hrs